Test your knowledge in a multiply relapsed multiple myeloma case

1. Talquetamab has both a weekly and an every-other-week subcutaneous dosing option.
True
False
2. According to the MonumenTAL-1 trial, what is the risk of cytokine release syndrome in patients treated with talquetamab?
Risk is low and not a concern
About 76% with 57% grade 2/3 adverse events
About 76% with 57% grade 1 adverse events
About 57% with 14% grade 1/2 adverse events
3. Patients on talquetamab need to be monitored for which of the following issues?
Skin and nail changes
Oral toxicities
Cytokine release syndrome and neurologic toxicity
All of the above
{"name":"Test your knowledge in a multiply relapsed multiple myeloma case", "url":"https://www.quiz-maker.com/QL2A6G705","txt":"1. Talquetamab has both a weekly and an every-other-week subcutaneous dosing option., 2. According to the MonumenTAL-1 trial, what is the risk of cytokine release syndrome in patients treated with talquetamab?, 3. Patients on talquetamab need to be monitored for which of the following issues?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys